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Hs-CRPAbstract Background: Asthma and COPD are characterized by chronic airway inﬂammation that
results in chronic airway obstruction which is reversible in asthma and non-reversible or partially
reversible in COPD. The differential diagnosis between reversible or irreversible airﬂow obstruction
due to asthma or COPD is important in clinical practice because the prognosis and the response to
treatment of the two diseases are different. Nitric oxide (NO) is produced by many cells within the
respiratory tract. Endogenous NO may play an important signaling role in the physiological control
of airway function and in the pathophysiology of airway diseases. Measurement of airway inﬂam-
mation by means of FENO may be useful and convenient for asthma diagnosis, particularly when
bronchial challenges and/or spirometric maneuvers cannot be correctly performed. The increase in
the percentage of peripheral blood and sputum eosinophils was found in patients with asthma that
correlated with the clinical severity of asthma and pulmonary function. Elevated levels of C-reactive
protein (CRP) are established in COPD but, in asthma, the results have been inconsistent. The aim
of the present study was to evaluate differences in local (airway) and systemic inﬂammatory mark-
ers among primary care patients with asthma and COPD using simple, rapid and easy to do tests.
Subjects and methods: One hundred and ﬁfty patients and thirty control subjects were included
in this study. They were divided into three groups, ninety asthmatic patients diagnosed clinically
and physiologically as reversible airway obstruction (group I). Sixty COPD patients diagnosed
by clinical, physiological and laboratory tests to have irreversible or partially reversible airway
obstruction (group II). The third group is the control group with no airway obstruction (NAO)
including thirty subjects. Pulmonary function tests, FENO, hs-CRP, blood and sputum eosinophil
percentages were done to all subjects.
Results: FENO was positively correlated with all inﬂammatory markers in the asthmatic group
with highly signiﬁcant differences (p 6 .001) and negatively correlated with age, BMI and PFTs. Ind.
14 A.M. Rawy, A.I. Mansourthe COPD group there was a positive correlation between FENO with all inﬂammatory markers
and PFT with highly signiﬁcant differences (p 6 .001) with sputum and blood eosinophils and
not signiﬁcantly correlated with hs-CRP and PFT.
Conclusion: It is concluded that there are signiﬁcant differences in inﬂammatory patterns
between asthma and COPD. FENO and hs-CRP had the highest ability to discriminate between
patients with asthma and COPD.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. All rights reserved.Background
Asthma and chronic obstructive pulmonary disease (COPD)
are increasingly important chronic airway diseases [1]. As well
known, asthma is a chronic airway disease characterized by the
presence of inﬂammatory cells and the release of proinﬂamma-
tory mediators in the airways. Conventional diagnosis of
asthma is made by means of the clinical history, measurement
of reversible airway obstruction (response to bronchodilators),
and an assessment of bronchial hyperresponsiveness by inhala-
tion challenges [2]. Also chronic obstructive pulmonary disease
(COPD) is simply considered a lung disease characterized by
the presence of ﬁxed and progressive airﬂow limitation derived
from airway inﬂammation/remodeling associated with the
parenchymal destruction the so-called pulmonary emphysema.
However, in most of the COPD patients the disease coexists
with several other systemic manifestations which can make
health-related quality of life worse and increase mortality [3].
Thus, COPD could no longer be deﬁned as a disease restricted
to the lung but might be considered part of a complex chronic
systemic disease [4].
Nitric oxide (NO) is produced by many cells within the
respiratory tract. Endogenous NO may play an important sig-
naling role in the physiological control of airway function and
in the pathophysiology of airway diseases [5]. Endogenous NO
is synthesized by the conversion of the amino acid L-arginine
to L-citrulline and NO by the enzyme NO synthase (NOS) of
which three distinct isoforms exist [6]. Two isoforms, neuronal
(nNOS, type I) and endothelial (eNOS, type III), are constitu-
tive and calcium dependant. Both are found in the airway
epithelium where they produce picomolar concentrations of
NO. The third is inducible (iNOS, type II) and calcium-
independent. This is expressed in vivo in the bronchial epithe-
lial cells in both healthy and asthmatic individuals and its
activity increases during certain inﬂammatory processes. It is
also expressed in vitro following stimulation by cytokines,
endotoxins and lipopolysaccharides and its induction is
blocked by glucocorticoids [7,8]. Inducible NOS produces
nanomolar concentrations of NO which remains stable in the
gaseous phase and can be assayed [9].
NOS isoforms also exist in the human pulmonary vascula-
ture, in the bronchial tree and in the parenchyma. NOS is
expressed in the following cell types: arterial and venous endo-
thelial cells, epithelial cells, macrophages, mast cells, neutro-
phils, eosinophils, non-adrenergic non-cholinergic nerves,
ﬁbroblasts, smoothmuscle cells and platelets. The rise in FENO
which is measurable in asthma in particular is attributable to its
increased production in bronchial epithelial cells. It plays animportant role in the recruiting and activation of eosinophilic
granulocytes [10,11].
Measurement of airway inﬂammation by means of FENO
may be useful and convenient for asthma diagnosis, particu-
larly when bronchial challenges and/or spirometric maneuvers
cannot be correctly performed [12]. Markers of airway inﬂam-
mation, such as eosinophils from induced sputum and airway
biopsy specimens, are elevated in patients with asthma and
have been found to correlate with FENO or bronchial hyper-
reactivity in patients not treated with inhaled corticosteroids
[13].
As a marker of eosinophilic airway inﬂammation, frac-
tional exhaled nitric oxide (FENO) is increased in patients with
asthma [14]. Serum immunoglobulin E (IgE) levels are known
to be associated with asthma [15], and a signiﬁcant increase in
the percentage of peripheral blood eosinophils was found in
patients with asthma that correlated with the clinical severity
of asthma and pulmonary function. Elevated levels of
C-reactive protein (CRP) are established in COPD [16–18]
but, in asthma, the results have been inconsistent. In recent
studies high-sensitivity CRP concentrations (hs-CRP) were
signiﬁcantly higher in asthma patients than in controls without
obstructive airways disease (OAD) [19,20].
FENO levels in COPD are of conﬂict [21], but it seems that
smoking habits and disease severity are the most important
factors inﬂuencing exhaled NO levels in these patients [22].
Current smokers [23] and severe COPD patients (particularly
in combination with cor pulmonale) [24] show lower levels of
exhaled NO than ex-smokers and mild/moderate COPD.
Increased exhaled NO levels have been reported in hospitalized
patients during an exacerbation of COPD [25]. Interestingly,
exhaled NO levels returned to control values only months after
discharge of those steroid treated patients, suggesting different
inﬂammatory mechanisms in COPD compared with the highly
steroid-sensitive asthmatics [25].
Aim of the study
The aim of the present study was to evaluate differences in air-
way and systemic inﬂammatory markers among primary care
patients with asthma and COPD. This might assist the differ-
entiation between asthma and COPD in primary care. Also to
evaluate FENO in asthmatic patients and to assess possible
correlations between these measurements and the results of
tests used in routine diagnosis of asthma (baseline lung func-
tion, reversibility of airway obstruction) and other laboratory
tests commonly associated with asthma as hs-CRP, percentage
of peripheral blood and sputum eosinophils.
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Study population and design
One hundred and ﬁfty patients and thirty control subjects were
included in this study during the period of one year, from May
2013 to April 2014 who attended pulmonary outpatient clinic.
They were divided into three groups, ninety asthmatic patients
diagnosed clinically and physiologically as reversible airway
obstruction (group I). Sixty COPD patients diagnosed by clin-
ical, physiological and laboratory tests to have irreversible or
partially reversible airway obstruction (group II). The third
group is the control group with no airway obstruction
(NAO) including thirty subjects. The exclusion criteria were
subjects with respiratory tract infections in the four weeks
prior to investigation and subjects with well known contraindi-
cations for bronchodilator reversibility testing namely, preg-
nancy, untreated hyperthyroidism, unstable coronary artery
disease, and cardiac arrhythmia.
A written consent was taken from all patients and subjects
included in this study after explanation about all the investiga-
tions that will be done. All patients and subjects were referred
to the lung function unit of the University Hospital for further
investigation. Structuredmedical histories and clinical examina-
tion were documented. All subjects underwent full spirometric
study, peripheral blood complete blood picture with differential
leukocytic count mainly eosinophils, hs-CRP, sputum eosino-
phil count and exhaled nitric oxide measurement. Patients were
instructed not to use any bronchodilator or inhaled steroid and
to stop smoking 12 h before visiting the lung function labora-
tory. The number of pack-years was calculated as years of smok-
ing · number of daily cigarettes. Body mass index (BMI) was
calculated as weight (kg)/square of height (m2).
Measurement of FENO, hs-CRP, and differential leukocytic
count
Patients underwent measurement of FENO using Niox Mino
analyzer (Aerocrine AG, Solna, Sweden) at a mouth ﬂow rate
of 50 mL/s over 10 s and a pressure of 10 cmH2O according to
the guideline recommendation [26]. This procedure was per-
formed at the lung function unit of the University Hospital
before doing spirometry as forced inspiratory and expiratory
maneuvers can lead to distorted FENO results [27].
Samples of peripheral venous blood were collected. Serum
hs-CRP levels were measured with a high-sensitivity nephelo-
metric assay (ADVIAR 2400 Hematology System, Siemens
Healthcare Diagnostics, and Deerﬁeld, IL, USA). Also differ-
ential leukocytic count was measured.
Sputum processing
Sputum from all patients was collected. If some patients did not
produce sputum, induction of sputum with nebulized
hypertonic saline was done. Sputum was treated by adding four
volumes of 0.1% dithiothreitol (DTT-Sputolysin 10%;
Calbiochem Corp, La Jolla, CA, USA) and mixed by rotating
for 30 min at 37 C, followed by four volumes of phosphate
buffered saline (PBS). The suspension was ﬁltered through
60 mm nylon gauze (Millipore, North Ryde, NSW, Australia)and a total cell count of leukocytes and viability was deter-
mined [28]. A differential cell count was obtained by counting
400 non-squamous cells on slides ﬁxed with methanol and
stained withMayGrunwald Giemsa. Eosinophils were enumer-
ated as the percentage of 400 cells on slides ﬁxed with methanol
and stained with chromotrope 2R. Metachromatic cells were
counted as the percentage of 1500 cells on slides ﬁxed in
Carnoy’s solution and stained with acidic toluidine blue. Cell
counts were performed using coded slides by investigators
blinded to the clinical characteristics of the subjects [29].
Pulmonary function tests
Before doing the test, ambient temperature and pressure were
entered with the patient data (age in years, weight in kilo-
grams, height in centimeters and sex) so that all results were
calculated as percent of predicted (% predicted) except for
FEV1/FVC. Pulmonary function tests were done using
Sensor-medics Vmax series, 2130 spirometer, V 6200 Autobox,
6200 DL. Flow/volume loop was performed to all cases.
Patients with forced expiratory volume in ﬁrst second
(FEV1) <80% of predicted received a bronchodilation test.
The test was done 20 min after 2 puffs of Salbutamol
(200 lg) via meter dose inhaler.
An obstructive airway disease (OAD) was diagnosed if
FEV1/forced vital capacity (FVC) was 60.7. The obstruction
was classiﬁed as fully reversible (indicating ‘asthma’) if the
postbronchodilator FEV1 was improved >12% and
>200 mL from baseline and lung volumes returned to the pre-
dicted normal range. The obstruction was classiﬁed as irrevers-
ible (indicating COPD) if the degree of reversibility in FEV1
was less than 12% compared with baseline and was below
200 mL. In case FEV1/FVC was >0.7 and still patient com-
plains of chest tightness, FEF25–75% will be taken as a mea-
sure for airway obstruction if it was 60.7. It indicates small
airway obstruction.
Statistical analysis
Quantitative data were presented as means and standard devi-
ation (SD) values. Student’s t-test was used for comparisons
between means of two groups. Pearson’s correlation coefﬁcient
was used to determine signiﬁcant correlations between the
different variables. The signiﬁcance level was set at p 6 0.05.
Statistical analysis was performed with SPSS version 19.0
(statistical package for scientiﬁc studies) for windows.
Boxplots were constructed to illustrate the dispersion of each
inﬂammatory marker by diagnosis.
Results
Patients’ demographic data show that the means of ages and
BMI for all groups are matched. There were 129 males and
51 females of who 66 were currently smoked, 37 ex-smokers
and 77 never smoked (Table 1). As regards pulmonary func-
tion tests, the mean value of FEV1/FVC was less than 70%
in asthmatic and COPD patients but above ninety in control
subjects with NAO. Also the means of FVC, FEV1 and
FEF25–75% were lesser in asthmatic and COPD patients than
control subjects (Table 2).
Table 1 Patients’ demographic data.
Asthma COPD Control (NAO)
Age (mean) ± SD 33.1 ± 10.01 30.8 ± 9.5 34.9 ± 11.9
BMI (mean) ± SD 28.17 ± 4.6 29.3 ± 8 29.8 ± 6.4
Gender
Male 68 39 22
Female 22 21 8
Smoking status
Current smoker 20 39 7
Ex-smoker 14 13 10
Never smoke 56 8 13
Table 2 Patients’ pulmonary function tests.
Asthma COPD Control
FVC 76.2 ± 18.3 72.2 ± 19.8 91.7 ± 6.1
FEV1 69 ± 17.8 69.6 ± 20.8 99.9 ± 7.4
FEV1/FVC 68.96 ± 10.5 67.6 ± 8.4 92.2 ± 4.1
FEF25–75% 46.97 ± 13.9 52.54 ± 12.4 110.02 ± 19
Figure 1 Box plots illustrating the distribution of (a) fractional
exhaled nitric oxide (FENO), (b) high-sensitivity C-reactive
protein (hs-CRP), (c) blood eosinophil % and (d) sputum
eosinophil % within the diagnostic groups.
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than asthma patients (p= 0.016) and subjects with no OAD.
All other inﬂammatory markers showed highly signiﬁcant dif-
ferences between asthma and COPD with much higher levels in
asthma (p 6 .001) (Table 3 and Fig. 1).
FENO was positively correlated with all inﬂammatory
markers in the asthmatic group with highly signiﬁcant differ-
ences (p 6 .001) and negatively correlated with age, BMI and
PFTs. In the COPD group there was a positive correlation
between FENO with all inﬂammatory markers and PFT with
highly signiﬁcant differences (p 6 .001) with sputum and blood
eosinophils and not signiﬁcantly correlated with hs-CRP and
PFT. In the control group with NAO, the FENO was posi-
tively correlated with sputum eosinophil % and negatively cor-
related with other inﬂammatory markers with highly
signiﬁcant difference in all variables (Table 4 and Fig. 2).
The results showed that percentage of sputum eosinophils
in asthmatic patient has the highest sensitivity (89%) but least
speciﬁcity (50%). FENO has the highest accuracy (sensitivity
79% and speciﬁcity 71%). Hs-CRP has the highest sensitivity
and speciﬁcity in COPD (92% and 59% respectively). FENO,
sputum and blood eosinophils have no role in the diagnosis of
COPD where sensitivity and speciﬁcity cannot be calculated
(Table 5).
Discussion
According to the Foundation for the National Institutes of
Health Biomarkers Consortium, biomarkers are deﬁned asTable 3 Patients’ local and systemic inﬂammatory markers.
Asthma COPD
ENO/ppb 66.1 ± 32.7 13.2 ±
Sputum eosinophils 39.8 ± 18.2 1.7 ±
Peripheral blood eosinophils 8.3 ± 5.5 3.2 ±
Hs-CRP 9.6 ± 7.001 12.2 ±‘‘characteristics that are objectively measured and evaluated
as indicators of normal biological processes, pathogenic pro-
cesses, or pharmacologic responses to therapeutic interven-
tion’’ [30]. The most useful biomarkers are those with the
most direct relationship between the marker and the central
pathobiological characteristics of a disease process.Control t-test p-value
4 20.3 ± 2.3 7.17 <.0001
1.1 3.9 ± 2.5 9.34 <.0001
1.3 2.6 ± 1.5 4.07 0.0002
4.9 3.8 ± 3.2 1.43 0.016
Table 4 Correlation coefﬁcient (r) and p-value of ENO with hs-CRP, sputum eosinophil peripheral, blood eosinophils, FEV1/FVC,
age and BMI in all of the three groups.
FENO
Asthma
n= 90
COPD
n= 60
Control
n= 30
r p r p r p
Hs-CRP 0.687 <.00001 0.2371 0.469631 0.0286 <.00001
Sputum eosinophils 0.883 0.000367 0.758 <.00001 0.1031 <.00001
Peripheral blood eosinophils 0.596 <.00001 0.6058 0.002132 0.0763 <.00001
FEV1/FVC 0.1086 0.647734 0.163 0.231849 0.4612 <.00001
Age 0.1428 0.000007 0.1616 <.00001 0.0393 <.00001
MBI 0.0608 0.000001 0.0328 <.00001 0.0899 0.001018
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Figure 2 Correlation coefﬁcient (r) for asthma and COPD groups: the levels above the horizontal axis represent positive correlation
while levels below it represent negative correlation.
Table 5 Sensitivity and speciﬁcity of inﬂammatory markers in the diagnosis of asthma and COPD.
Asthma COPD
Sensitivity (%) Speciﬁcity (%) Sensitivity (%) Speciﬁcity (%)
ENO/ppb 79 71 – –
Sputum eosinophils 89 50 – –
Peripheral blood eosinophils 79 61 – –
Hs-CRP 68 57 92 59
Differences in airway and systemic inﬂammatory markers among asthma and COPD pateints 17Eosinophil count in induced sputum and FENO can both
serve as direct biomarkers for asthma inﬂammation in the
lungs. These biomarkers are advantageous in that they tend
to remain elevated even when patients are asymptomatic,
and decrease in the presence with ICS. Sputum induction is
safe and reproducible, though it is a semi-invasive procedure
which cannot be successfully accomplished in up to 13% of
adult patients with asthma, and even in a greater percentage
of children [31]. The technique of measuring FENO, in con-
trast, is non-invasive and well-tolerated. FENO measurements
are instantaneous, thus, facilitating decision-making at the
point of care.
Asthma and COPD are characterized by chronic airway
inﬂammation that results in chronic airway obstruction which
is reversible in asthma and non-reversible or partially revers-
ible in COPD. The differential diagnosis between reversibleor irreversible airﬂow obstruction due to asthma or COPD is
important in clinical practice because the prognosis and the
response to treatment of the two diseases are different [32].
The current study had evaluated the use of FENO measure-
ment to differentiate between both diseases in comparison with
other inﬂammatory markers. Variables such as sex, current
asthma, allergic rhinitis, smoking, current use of inhaled corti-
costeroids, atopy and seasonality have all been previously
identiﬁed as important explanatory factors that inﬂuence
FENO levels [33–36].
The most important ﬁnding of the present study is that
there were distinctive inﬂammatory proﬁles in patients with
asthma compared with COPD patients, thereby identifying dif-
ferent aspects of inﬂammation in OAD. The results of this
study showed that asthma has higher levels of FENO, sputum
and blood eosinophil percentage which were in agreement with
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COPD patients. The overall, hs-CRP had the highest diagnos-
tic accuracy in COPD with higher levels in COPD than in
asthma matched with other previous studies [32,37]. The
results of the study showed that exhaled nitric oxide is a weak
predictor in patients with COPD and that a normal or low test
result could help clinicians decide to avoid prescriptions of oral
corticosteroid treatment that may be unnecessary. This result
was in agreement with other previous study [38].
These observations help us to expect that those patients
with COPD would have greater systemic inﬂammatory marker
activation and those with asthma would have more local
inﬂammatory marker activation. Consistent with other
research, the sensitivities and speciﬁcities of FENO showed
that it is a good test for ruling asthma out but not so good
at ruling it in. This is due to the increase in FENO in bronchial
hyperreactivity and other eosinophilic inﬂammatory disorders
specially if not associated with airway obstruction. Similar but
less discriminatory ﬁndings were reported for blood eosino-
philia. Hs-CRP had reasonable sensitivity but a speciﬁcity of
only 50% for COPD, so had a high false positive rate
(Table 5).
As regards smoking, the number of pack-years was posi-
tively correlated with hs-CRP levels. Thus, smoking history
may inﬂuence the levels of inﬂammatory markers. The correla-
tion was even stronger when the analysis was restricted to sub-
jects with OAD.
Age was found to be negatively correlated with FENO in
the present study. Possible mechanisms included airway sur-
face area-related changes in NO diffusion coefﬁcients and
age-dependent recurrent immunologic stimulation leading to
the induction of NOS [39–41]. As regards effect of sex on the
results, there was an independent negative association of
female sex with FENO, consistent with previous studies [42–
48]. The sex effect could be due to differences in airway surface
area, diameter, and NO dilution [49] variants in the neuronal
NOS 1 gene [50] and the suppressive effects of estrogen on
NO synthase expression [43].
It has been demonstrated that standardized FENO mea-
surements performed with NIOX system are simple, free
from diurnal and day-to-day variation and acceptable by
patients. Exhaled nitric oxide measurement provides immedi-
ate non-invasive measurement of the airway inﬂammatory sta-
tus. This quick, easy and non-invasive tool can help in a good
control and management of asthma. The ENO value improves
diagnostic accuracy [51,52], predicts steroid response [53] and
determines the best treatment for chronic cough [54]. Both
low and high values are of clinical signiﬁcance [55]. It improves
the patient’s understanding and improves the compliance
[56,57]. It is cost effective [58], optimizes dose-adjustments
[59,60]. It predicts asthma relapse [61].Conclusion
The results of the current study conclude that there are signif-
icant differences in inﬂammatory patterns between asthma
and COPD. In COPD patients there is an increase in hs-CRP
concentrations whereas blood eosinophils, FENO, and sputum
eosinophils were increased in patients with asthma. FENO and
hs-CRP had the highest ability to discriminate between patients
with asthma and COPD. Exhaled nitric oxide measurementprovides, simple, immediate and non-invasive measurement
of the airway inﬂammatory status.
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